{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6"},{"groupId":"OG001","value":"2.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"376"}],"units":"Participants"}],"groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.","id":"OG001","title":"Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)"}],"paramType":"NUMBER","populationDescription":"The baseline ADA-evaluable population for each study treatment included patients who had a baseline ADA result. The post-baseline ADA-evaluable population for each study treatment included patients who had at least one post-baseline ADA result and had received at least on dose of that study treatment.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 29 months","title":"Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}